Benefit–risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir

Overview of attention for article published in Drug, Healthcare and Patient Safety, March 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#11 of 160)
High Attention Score compared to outputs of the same age (91st percentile)
Good Attention Score compared to outputs of the same age and source (66th percentile)

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 1,252 followers.

Benefit–risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir http://t.co/rQFPzJlc4a

Benefit–risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir http://t.co/1yFU3mbRw2

Benefit–risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir http://t.co/qvfBO6QFBW